Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child
Doctors treated a boy with rare leukemia and spinal pressure using special drugs
This is a case report with a systematic review of 11 published cases of TTMV::RARA-positive acute promyelocytic leukemia (APL). The authors …
A nine-year-old boy had rare leukemia and spinal cord pressure. Doctors used specific drugs that helped clear the disease and fix his spine.
Review of ATRA and ATO induction therapy in acute promyelocytic leukemia with RNA sequencing insights
Why PCR Missed This Leukemia
This case report and literature review examines induction therapy using all-trans retinoic acid and arsenic trioxide in acute promyelocytic …
A standard blood test missed a dangerous leukemia because the disease had a unique genetic pattern that routine screening overlooked until a…
Phase II trial shows high remission and survival with frontline ATRA-ATO for newly diagnosed APL
Can a chemotherapy-free treatment beat a rare, aggressive leukemia?
A prospective multicenter phase II trial in 81 newly diagnosed APL patients in Japan found that frontline ATRA-ATO therapy achieved a 95.1% …
A chemotherapy-free treatment for acute promyelocytic leukemia achieved 95% remission and 95% survival three years later in a Japanese trial…
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort
Can a simple blood test help diagnose leukemia? An AI tool shows promise but still needs work
An AI tool was tested on a retrospective, international cohort of 6206 leukemia patients from 20 centers to predict acute leukemia subtypes …
An AI tool can spot leukemia from standard blood tests but must refuse to guess for most patients until doctors refine it to help more peopl…
Research across Leukemia
Related studies from across the Leukemia family.
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML
Specific gene mutations linked to worse outcomes in certain leukemia
This meta-analysis of 4,363 patients found that MRG mutations (such as ASXL1, BCOR, and EZH2) are associated with inferior overall survival …
New data shows that specific gene mutations can predict poorer survival and lower remission rates for patients with a specific type of leuke…
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients
Treosulfan Shows Better Outcomes for Patients with Acute Myeloid Leukemia
This Phase 3 randomized trial subgroup analysis of 352 patients with AML undergoing alloHCT found treosulfan-fludarabine superior to reduced…
A new analysis of a Phase 3 trial suggests treosulfan may offer better survival rates and fewer complications for patients with acute myeloi…
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML
Lower Dasatinib Dose May Improve Tolerability for Leukemia Patients
This meta-analysis of 7 nonoverlapping reports compared dasatinib 50 mg and 100 mg in adults with chronic-phase chronic myeloid leukemia. Th…
A lower daily dose of dasatinib may offer similar effectiveness with fewer side effects for adults with chronic-phase chronic myeloid leukem…
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients
Trial Shows Early Markers Predict Success in Chronic Myeloid Leukemia
This observational study of 431 patients with chronic myeloid leukemia (CML) on second-generation TKIs found that the 6-month IS value is a …
New data from a Phase 3 trial shows that early markers can help predict which patients with chronic myeloid leukemia may reach specific trea…
Pirtobrutinib Combined with Venetoclax and Rituximab Improves Progression Free Survival
Trial shows pirtobrutinib improves survival for chronic lymphocytic leukemia
Adding pirtobrutinib to a venetoclax-rituximab regimen significantly extends progression-free survival in patients with chronic lymphocytic …
A new combination treatment involving pirtobrutinib may help patients with chronic lymphocytic leukemia live longer without their cancer pro…
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature
AI for leukemia diagnosis still fragmented, review finds
This scoping review evaluates deep learning techniques for leukemia detection across morphological, immunophenotyping, and molecular modalit…
A new review shows AI tools for leukemia diagnosis are promising but fragmented, with few using multiple data types.
Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosis
Leukapheresis Shows No Clear Early Death Benefit in AML
This meta-analysis of 1406 adults with AML and hyperleukocytosis found that leukapheresis was not clearly associated with lower 30-day morta…
A review of 1406 AML patients found leukapheresis did not clearly lower 30-day death risk. Evidence is weak.
AML infiltration of bile duct identified as primary cause of acute pancreatitis in case report
Leukemia Cells Found as Cause of Severe Pancreatitis
This case report and literature review describes a 34-year-old man with acute pancreatitis and type 2 diabetes, where acute myeloid leukemia…
A rare case shows how a specific type of leukemia can infiltrate the pancreas and cause severe inflammation in patients with diabetes.
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia
PEG-asparaginase shows lower toxicity in childhood leukemia trial
This Phase 3 randomized controlled trial evaluated intravenous PEG-asparaginase (IV-PEG) versus intramuscular native E. coli L-asparaginase …
A new trial finds that PEG-asparaginase may cause fewer side effects than standard treatment for children with leukemia.
TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework
One patient's leukemia remission offers clues for rare diagnosis
This systematic review with a case report describes a patient with Philadelphia chromosome-positive leukemia who achieved complete remission…
A patient with a rare leukemia achieved deep remission for 35 months. The case highlights how to tell apart two similar-looking blood cancer…
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia
Imatinib works for CML in child with high platelets
This case report describes a pediatric patient with isolated thrombocytosis who achieved a complete cytogenetic response to imatinib after f…
A child with high platelets and no response to standard therapy was found to have CML and responded to imatinib.
Questions about Acute Promyelocytic Leukemia
How effective is frontline ATRA-ATO therapy for newly diagnosed Acute Promyelocytic Leukemia?
Frontline ATRA-ATO therapy is highly effective for newly diagnosed APL, with complete remission rates over 94% and 3-year survival above 93% in clinical trials.
Full answer →Does the new AI test work well for distinguishing Acute Promyelocytic Leukemia from other types?
An AI tool shows very high accuracy for distinguishing Acute Promyelocytic Leukemia (APL) from other leukemias, with an AUROC of 0.98 in international tests, though it currently excludes many patients from predictions.
Full answer →What are the survival rates for Acute Promyelocytic Leukemia treated with ATRA and ATO?
ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.
Full answer →